SUNPHARMA
vs
B
BSE Sensex 30
SUNPHARMA
Over the past 12 months, SUNPHARMA has underperformed BSE Sensex 30, delivering a return of +11% compared to the BSE Sensex 30's +12% growth.
Stocks Performance
SUNPHARMA vs BSE Sensex 30
Performance Gap
SUNPHARMA vs BSE Sensex 30
Performance By Year
SUNPHARMA vs BSE Sensex 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Sun Pharmaceutical Industries Ltd
Glance View
Sun Pharmaceutical Industries Ltd. began its journey in 1983 with a vision to provide quality healthcare to billions worldwide. Originating from India, Sun Pharma has steadily emerged as a global leader in the pharmaceutical industry. The company’s strength stems from its ability to efficiently manufacture, develop, and market a wide range of generic pharmaceuticals and therapeutic formulations. With a significant footprint in over 100 countries, it is driven by a robust pipeline of drugs encompassing key therapeutic areas such as psychiatry, cardiology, neurology, and gastroenterology. A hallmark of Sun Pharma’s strategy has been its strong focus on research and development, specifically in creating affordable medicines that tackle complex medical conditions. The company’s business model revolves around a dual strategy: the development of complex generics and innovative specialty products. This approach allows Sun Pharma to capitalize on both the high-volume, cost-efficient production of off-patent drugs and the value-driven, specialized therapy segments. By leveraging its R&D capabilities, the company explores new drug delivery systems and complex formulations, which not only ensure a steady flow of new product introductions but also enhance its competitive edge in the market. This blend of innovation and scale positions Sun Pharmaceutical Industries Ltd. as a dynamic force in the global pharmaceutical landscape, continually navigating the intricate balance of providing both profitable growth and accessible healthcare solutions.
